摘要
探讨治疗晚期原发性肝癌 (简称晚期肝癌 )有效的方法和途径。方法 :晚期肝癌141例随机分两组 :A组 (对照组、一次性插管组 )85例 ,按常规每月一次插管介入化疗栓塞治疗。B组 (治疗组、药盒系统组 )56例 ,常规每月一次插管介入化疗栓塞并经左锁骨下动脉植入药盒系统 ,连续灌注HCPT10d ,10mg/d。结果 :根据WHO标准判断疗效A组 :CR1例 (1 2 % ) ,PR41例 (48 2 % ) ,NC37例 (43 5 % ) ,PD6例 (7 1 % ) ,CR +PR42例 (49 4 % ) ;B组 :CR2例 (3 6 % ) ,PR36例 (64 3 % ) ,NC18例 (32 1 % ) ,PD4例 (7 1 % ) ,CR +PR38例(67 8 % ) ,两组相比有显著差异 (P<0 05)。生存期 :A组最短2月 ,最长26月 ,中位数13月 ;B组最短5月 ,最长39月 ,中位数16月 ,B组优于A组 ,但无显著性差异 (P>0 05)。毒副作用两组相比无显著性差异 (P>0 05)。结论 :经皮左锁骨下动脉导管药盒系统植入术操作简单、损伤小、并发症少、疗效高 。
Objective: To evaluate the efficiency of therapy for advanced primary hepatic carcinoma Methods: A total of 141 cases of advanced primary hepatic carcinoma were divided into 2 groups:(1)group A: 85 patients were treated once a month with transcatheter arterial embolization ( TAE) or Transcatheter arterial infusion(TAI) (2)group B: 56 patients were treated as group A hydroxyl camptothecine (HCPT) intra arterially through percutaneous left subclavian artery port catheter system implantation (PSPI) 10mg a day for 10 days every month Result: The response rate (CR+PR) was 49 4%and 67 8%in group Aand group B (P<0 05),respectively The survival rate of ～0 6, ～1, ～2, ～3 and 3～years was 36 5%, 49 4%, 14 1%, 0%and 0%in group A but 16 1%, 57 1%, 23 2%, 1 8%and 1 8%in group B Conclusion: PSPI isa efficient therapy for advanced primary hepatic carcinoma
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2000年第8期792-794,共3页
Chinese Journal of Cancer
关键词
肝肿瘤
药物疗法
植入药盒
介入疗法
Liver neoplasms
Drug therapy
Catheters indwelling
Radiology interventional
